India’s Natco Pharma, a company that specializes in complex generics, plans to build up its business in China, taking advantage of China’s speeded-up approval process to register products that are already approved elsewhere. Natco has...
Read moreNanjing Frontier Biotechnologies was approved to stage a $285 million IPO on the Shanghai STAR Exchange. Frontier has a China approved treatment for HIV, and it is developing another HIV treatment that it in-licensed from the Rockefeller...
Read moreBeijing Baicare Biotech closed a $9 million B financing that was led by Sinopharm Capital and included the company’s existing shareholders. Formed in 2013, Baicare makes automated nucleic acid detection devices for clinical use using...
Read moreAIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy...
Read moreThe U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
Read moreQiyu Biotechnology, a Shanghai startup located in Zhangjiang Hi-Tech Park, completed a Series A round that raised “tens of millions of RMB” from Jundu Investment and Wosheng Capital. This proceeds are earmarked to support the...
Read moreBio-Thera Solutions of Guangzhou has begun a China Phase I trial to examine the pharmacokinetics and safety of its BAT2506, a proposed biosimilar to Simponi® (golimumab), a Janssen treatment for arthritis/ulcerative colitis. The comparison trial...
Read moreINVICTUS Achieved Primary Endpoint, Ripretinib Significantly Improved Progression Free Survival (PFS) Versus Placebo in Patients with Fourth-line and Fourth-line Plus GIST Median PFS for Ripretinib of 6.3 Months Versus Placebo of 1.0 Month...
Read moreCStone, a Suzhou biopharma, has dosed the first patient in the China arm of a global Phase I registrational study of BLU-667, a RET-inhibitor, in patients with various solid tumor cancers. One year ago, CStone in-licensed greater China rights to...
Read moreAslan Pharma of Singapore provided an update on the progress of its three clinical-stage oncology and immunology candidates: • The company signed up K-MASTER to run a 400 patient South Korean Phase Ib/II trial of its lead drug, varlitinib, in...
Read moreDelMar Pharma of Vancouver and Menlo Park reported early results from its China Phase II trial of VAL-083 as a first line treatment for glioblastoma multiforme. VAL-083 is being administered along with radiation to patients with newly-diagnosed...
Read moreAscletis Pharma Inc.(1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its...
Read more
